The CD38 ectoenzyme family: advances in basic science and clinical practice

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• B-cell Chronic Lymphocytic Leukemia (B-CLL) is a heterogeneous lymphoid malignancy.
• CD38 expression is a known factor in B-CLL, but its precise role in disease pathogenesis and prognosis requires further elucidation.

Purpose of the Study:

• To review the role of CD38 in B-cell Chronic Lymphocytic Leukemia (B-CLL).
• To evaluate CD38 as a potential therapeutic target in B-CLL.
• To analyze the correlation between CD38 expression and clinical features, including prognosis.

Main Methods:

• Analysis of CD38 expression levels in B-CLL patient samples.
• Correlation of CD38 expression with phenotypic features, proliferation markers (Ki-67), telomerase activity, and IgVH mutational status.
• Investigation of CD38 expression in bone marrow B-cells to establish a cut-off for predicting time to treatment.

Main Results:

• CD38(high) B-CLL cases exhibit activated phenotypes, increased Ki-67, and telomerase activity compared to CD38(low) cases.
• A CD38 cut-off value <10% in bone marrow B-cells predicts a longer time to treatment.
• CD38 expression, along with other factors, aids in stratifying B-CLL patients into distinct risk groups (low, intermediate, high) with different clinical courses.

Conclusions:

• CD38 expression is linked to B-CLL cell activation, differentiation stage, and proliferative potential.
• CD38 plays a role in the pathogenetic network of B-CLL and contributes to disease aggressiveness.
• CD38 serves as an independent prognostic marker for B-CLL, suggesting its utility in clinical risk stratification and as a therapeutic target.